AcelRx cures Nasdaq minimum bid price deficiency; compliance regained

TALPHERA, INC.

Nasdaq had notified AcelRx on April 26, 2023 of non-compliance with the $1.00 minimum bid price rule.
On June 15, 2023, Nasdaq confirmed the company cured the deficiency and regained compliance.
The bid price deficiency matter is now closed with no further action required.

item 8.01

TALPHERA, INC. filing history →

Source: SEC EDGAR

accession 0001437749-23-017562

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.